| Trial ID: | L6264 |
| Source ID: | NCT05814107
|
| Associated Drug: |
Ct-996
|
| Title: |
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Overweight or Obesity
|
| Interventions: |
DRUG: CT-996|DRUG: Placebo
|
| Outcome Measures: |
Primary: Incidence of Treatment-Emergent Adverse Events in CT-996 participants, To evaluate the safety and tolerability of CT-996, Baseline up to 28 days | Secondary: Maximum observe drug concentration (Cmax) of CT-996, PK Cmax, Baseline up to 28 days|Effect of a High-Fat Meal on Plasma Concentration of CT-996, Determine the effect of a high-fat meal on the PK of CT-996 following a single dose, Baseline up to 14 days
|
| Sponsor/Collaborators: |
Sponsor: Carmot Australia First Pty Ltd | Collaborators: Carmot Therapeutics, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
118
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2023-05-09
|
| Completion Date: |
2024-11
|
| Results First Posted: |
|
| Last Update Posted: |
2023-06-15
|
| Locations: |
Carmot Clinical Research Unit 101, Melbourne, Australia
|
| URL: |
https://clinicaltrials.gov/show/NCT05814107
|
